Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 7.6 3.26% 0.24
RUBY closed up 3.26 percent on Monday, November 18, 2019, on 1.15 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RUBY trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 3.26%
New 52 Week Closing Low Bearish 3.26%

Older signals for RUBY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Autoimmune Disease Therapies For Cancer Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
Is RUBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.98
52 Week Low 6.96
Average Volume 318,112
200-Day Moving Average 13.3514
50-Day Moving Average 9.1373
20-Day Moving Average 9.4305
10-Day Moving Average 9.592
Average True Range 0.9719
ADX 25.14
+DI 11.4525
-DI 26.5709
Chandelier Exit (Long, 3 ATRs ) 8.2843
Chandelier Exit (Short, 3 ATRs ) 9.8757
Upper Bollinger Band 11.4002
Lower Bollinger Band 7.4608
Percent B (%b) 0.04
BandWidth 41.772971
MACD Line -0.1759
MACD Signal Line 0.1183
MACD Histogram -0.2942
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.43
Resistance 3 (R3) 8.39 8.09 8.29
Resistance 2 (R2) 8.09 7.88 8.10 8.24
Resistance 1 (R1) 7.84 7.75 7.97 7.88 8.20
Pivot Point 7.54 7.54 7.60 7.55 7.54
Support 1 (S1) 7.29 7.33 7.42 7.33 7.00
Support 2 (S2) 6.99 7.20 7.00 6.96
Support 3 (S3) 6.74 6.99 6.91
Support 4 (S4) 6.78